Attending Training Courses on Barrett’s Esophagus Improves Adherence to Guidelines: A Survey from the Italian Society of Digestive Endoscopy

Rocco Maurizio Zagari1 · Leonardo Henry Eusebi1 · Giuseppe Galloro2 · Stefano Rabitti1 · Matteo Neri3 · Luigi Pasquale4 · Franco Bazzoli1

Received: 24 May 2020 / Accepted: 14 September 2020 / Published online: 28 September 2020 © The Author(s) 2020

Abstract

Background Little is known on practice patterns of endoscopists for the management of Barrett’s esophagus (BE) over the last decade.

Aims Our aim was to assess practice patterns of endoscopists for the diagnosis, surveillance and treatment of BE.

Methods All members of the Italian Society of Digestive Endoscopy (SIED) were invited to participate to a questionnaire-based survey. The questionnaire included questions on demographic and professional characteristics, and on diagnosis and management strategies for BE.

Results Of the 883 SIED members, 259 (31.1%) completed the questionnaire. Of these, 73% were males, 42.9% had > 50 years of age and 68.7% practiced in community hospitals. The majority (82.9%) of participants stated to use the Prague classification; however 34.5% did not use the top of gastric folds to identify the gastro-esophageal junction (GEJ); only 51.4% used advanced endoscopy imaging routinely. Almost all respondents practiced endoscopic surveillance for non-dysplastic BE, but 43.7% performed eradication in selected cases and 30% practiced surveillance every 1–2 years. The majority of endoscopists managed low-grade dysplasia with surveillance (79.1%) and high-grade dysplasia with ablation (77.1%). Attending a training course on BE in the previous 5 years was significantly associated with the use of the Prague classification (OR 4.8, 95% CI 1.9–12.1), the top of gastric folds as landmark for the GEJ (OR 2.45, 95% CI 1.27–4.74) and advanced imaging endoscopic techniques (OR 3.33, 95% CI 1.53–7.29).

Conclusions Practice patterns for management of BE among endoscopists are variable. Attending training courses on BE improves adherence to guidelines.

Keywords Barrett’s esophagus · Diagnosis · Surveillance · Treatment

Introduction

Barrett’s esophagus (BE) is a complication of gastro-esophageal reflux disease characterized by the replacement of the stratified squamous epithelium of the distal esophagus with specialized columnar epithelium [1]. Barrett’s esophagus is a well-known precancerous condition that through the development of low- and high-grade dysplasia could evolve into esophageal adenocarcinoma [1]. The incidence of BE has been rising over the last decade, particularly in Europe [2, 3], together with an increase in the incidence of esophageal adenocarcinoma [4]. Unfortunately, the mortality for esophageal cancer is extremely high with 5-years survival rates of less than 20% [5].
An appropriate diagnosis and management of BE is crucial to improve secondary prevention for esophageal adenocarcinoma, reducing mortality and disease-related costs. The introduction of the endoscopic Prague C&M classification [6] and “Seattle” biopsy sampling protocol [7], along with advanced imaging endoscopic techniques (high-definition endoscopy with dye or virtual cromoendoscopy) [8] and an appropriate endoscopic surveillance [9] have certainly improved the detection of dysplasia and early esophageal adenocarcinoma in BE. Moreover, novel endoscopic techniques, such as mucosectomy and radiofrequency ablation, have shown to be effective and safe for treating superficial neoplastic lesions in BE [10, 11].

Several international guidelines have been released and updated in order to improve the management of BE, inducing changes and innovation to diagnosis, surveillance and treatment modalities [12]. However, several studies highlighted the presence of a substantial variability in the adherence of physicians to BE guidelines [13, 14]. Indeed, little is known on the practice patterns of endoscopists in the management of BE, in particular in Europe, over the last decade. In fact, only four questionnaire-based surveys, one in Europe (the ESGE survey) [15], two in the USA [16, 17] and one in Australia [18], have been conducted to assess the current practice of gastroenterologists for the diagnosis and management of BE. A better knowledge of practice patterns of endoscopists regarding the management of BE is essential to guide and implement interventions, including training courses, that may improve their adherence to guidelines.

The aim of this survey was to assess practice patterns of endoscopists in the diagnosis, surveillance and treatment of Barrett’s esophagus in Italy.

**Methods**

This survey was conducted by the Italian Society of Digestive Endoscopy (SIED) between March and July 2016. All 883 members of SIED were invited to participate to the survey, after excluding members still in training or retired. A self-administered questionnaire was distributed to the attendees of the annual SIED National Course, held in Siena in March 2016, whereas an on-line version of the questionnaire was sent by email to the remaining SIED members who did not attend the course. There were no incentives for the participation to the survey. This survey study was an initiative of the Scientific Committee of the Italian Society of Digestive Endoscopy and was conducted after it was approved by the Governing Council of the Society itself. Written informed consent to anonymous use of data provided in the questionnaire was individually obtained from all participant endoscopists.

**Questionnaire Development**

The questionnaire was developed by the SIED scientific board committee and was based on most recent BE international guidelines, position statements and questionnaires [15, 16, 19–22].

The questionnaire had three sections. The first section included six questions regarding demographic and professional characteristics of the participant endoscopists, such as age (< 30, 30–40, 41–50, 51–60, > 60 years), gender, area of residence, practice setting (community hospital, university hospital or private hospital) duration of endoscopic activity (< 5, 5–10, 11–15, 16–20, > 20 years) and attendance to a BE training course over the last 5 years. The second section included five questions regarding the diagnosis of BE, such as the landmark used to define the gastro-esophageal junction (GEJ), the use of the Prague classification, the use of “Seattle” biopsy protocol and the use of advanced endoscopic imaging techniques. Finally, the third section included six questions on endoscopic surveillance and treatment of non-dysplastic and dysplastic BE.

**Statistical Analysis**

We performed descriptive analyses using percentages for categorical variables, and we calculated statistical differences between percentages using the Chi Square test. Multivariate logistic regression analyses were performed to investigate factors associated with different practice patterns for the management of BE. Odds Ratios (OR) and 95% confidence interval (CI) were calculated after adjusting for gender, age, practice duration and practice setting. A p value < 0.05 was considered statistically significant. Statistical analysis was performed using STATA (StataCorp, College Station, Texas).

**Results**

Of the 883 members of SIED, 259 completed the questionnaire with a response rate of 31.1%. Not all participants answered to all the questions, thus the number of responses for each variable varied accordingly. Among the participants, 73% were males, 42.9% had > 50 years of age and 65.6% had > 10 years of practice. The majority of endoscopists (68.8%) practiced in community hospitals, whereas 23.4% worked at University hospitals. Slightly more than half (61%) of endoscopists attended a training course on Barrett’s esophagus in the last 5 years.
Participants to the survey were similar to the eligible population of SIED members in terms of age, gender, area of residence and practice setting. Table 1 shows demographic and professional characteristics of participants and SIED members.

**Diagnosis of Barrett’s Esophagus**

The majority (82.9%, 214/258) of endoscopists reported to measure the extent of BE using the Prague classification and to perform biopsy sampling according to the Seattle protocol (84.4%, 216/256). However, only 65.5% (167/255) of participants used the top of the gastric folds to identify the GEJ, while 27.1% (69/255) used the Z line, 5.9% (15/255) the distal end of palisade vessels and 1.6% (4/255) the diaphragmatic hiatus. The presence of intestinal metaplasia was required for diagnosis of BE by 88.3% (226/256) of participants. Only half (51.4%, 131/255) of respondents used routinely advanced endoscopic imaging techniques, such as high-definition (HD) endoscopy, narrow band imaging (NBI), autofluorescence imaging (AFI) and confocal laser endomicroscopy (confocal); 29.4% (75/255) used advanced imaging only in patients with suspected dysplasia or cancer. Table 2 shows in detail the practice patterns of the participants for the diagnosis of BE.

**Management of Barrett’s Esophagus**

Almost all participants (99.6%, 253/254) practiced endoscopic surveillance for BE without dysplasia; however, 43.7% (111/254) performed eradication treatment of non-dysplastic BE in selected cases, such as those with young age (< 40 years) at diagnosis, long segment BE (> 3 cm) or family history for esophageal cancer. As for the frequency of surveillance, 69.2% (176/254) of endoscopists practiced endoscopic surveillance every 3–5 years, 23.3% (60/254) every 2 years and 6.7% (17/264) every year. Barrett’s esophagus with low-grade dysplasia was managed with endoscopic surveillance by 79.1% (201/254) of endoscopists, with 53.9% (137/254) performing eradication treatment only to selected cases (age < 40 years at diagnosis, long segment BE > 3 cm, family history for esophageal cancer), whereas 20.9% (53/254) practiced endoscopic eradication to all patients. Patients with low-grade dysplasia received endoscopic surveillance yearly by 84.8% (196/231) of respondents. The majority (77.1%, 188/244) of endoscopists managed BE with high-grade dysplasia or intramucosal adenocarcinoma with an endoscopic treatment, whereas only 16.3% (40/231) refused such patients to surgery. In total, 62.9% (146/232) of endoscopists were able to perform endoscopic eradication techniques, whereas 37.1% (186/232) was not. The most frequently endoscopic techniques performed by participants were endoscopic mucosal resection (46.7%) and radiofrequency ablation (29.7%). Table 3 shows the practice patterns of the participants for the surveillance and treatment of BE.

**Predictors for Practice Patterns**

A multivariate regression analysis showed that attending a training course on the management of BE during the previous 5 years was significantly associated with the use of the Prague classification (OR 4.8, 95% CI 1.9–12.1, \( p = 0.001 \)), the top of the gastric folds as landmark for the GEJ (OR 2.45, 95% CI 1.27–4.74, \( p = 0.008 \)) and the use of advanced imaging endoscopic techniques (OR 3.33, 95% CI 1.53–7.29, \( p = 0.003 \)) (Table 4). Male endoscopists attended a training course on BE more frequently than females (79% vs. 63.4%, OR 2.37, 95% CI 1.16–4.82, \( p = 0.017 \)) (Table 4).
Discussion

Our survey showed that the practice patterns of endoscopists for the management of BE are still variable. The majority of participants referred to use the Prague classification to measure the extension of BE; however about one third used incorrectly the Z line as landmark for the GEJ. Only half of the endoscopists used advanced endoscopic imaging techniques routinely. Almost all respondents practiced endoscopic surveillance for non-dysplastic BE; however, one third performed endoscopic eradication treatment in selected cases, and one third practiced frequent endoscopic surveillance, every 1–2 years. The majority of participants managed low-grade dysplasia with endoscopic surveillance and high-grade dysplasia or intramucosal carcinoma with endoscopic treatment. Endoscopists who used the Prague classification, including the top of the gastric folds as landmark for the GEJ, and used advanced imaging endoscopic techniques were more likely to have attended a training course on BE during the previous 5 years.

In our survey, the majority of endoscopists used the Prague classification, in line with the ESGE survey where this classification was used by 78% of respondents from European countries [15], but in contrast with surveys from the USA that showed a less frequent use (22–53% of participants) [16, 17]. However, we found that about one third of participants incorrectly used the Z line, which is the landmark of the squamo-columnar junction, to define the location of the GEJ. Notably, the diagnosis of BE encompasses the endoscopic recognition of the GEJ, which defines the true end of the esophagus. The definition of the endoscopic landmark that best identifies the GEJ is still controversial and there is not a universally accepted definition. In Asia, the distal end of palisade vessels is used as GEJ landmark, and it could be applied also in Western countries [23]. Nevertheless, current guidelines recommend the use of the proximal extent of the gastric folds as it is considered the best and
### Table 3 Practice patterns of participants in the management of Barrett’s esophagus (BE)

| Management of BE without dysplasia | Participants \( n \) (\%) |
|-----------------------------------|-----------------------------|
| **My management of BE without dysplasia is:**                                    |                             |
| Total                             | 254                         |
| Endoscopic surveillance in all patients | 142 (55.9)          |
| Endoscopic surveillance with eradication treatment in selected cases<sup>a</sup> | 111 (43.7)          |
| Endoscopic eradication treatment for all patients | 0                         |
| Neither surveillance or endoscopic treatment | 1 (0.4)            |
| **I perform surveillance of BE without dysplasia:**                              |                             |
| Total                             | 254                         |
| Yearly                            | 17 (6.7)                    |
| Every 2 years                     | 59 (23.2)                   |
| Every 3 years                     | 157 (61.8)                  |
| Every 4 years                     | 2 (0.8)                     |
| Every 5 years                     | 17 (6.7)                    |
| > 5 years                         | 2 (0.8)                     |
| **My management of BE with low-grade dysplasia is:**                             |                             |
| Total                             | 254                         |
| Endoscopic surveillance           | 64 (25.2)                   |
| Endoscopic surveillance with eradication treatment in selected cases<sup>a</sup> | 137 (53.9)          |
| Endoscopic treatment for all patients | 53 (20.9)            |
| No surveillance or endoscopic treatment | 0                         |
| **I perform surveillance of BE with low-grade dysplasia:**                      |                             |
| Total                             | 231                         |
| Yearly                            | 196 (84.8)                  |
| Every 2 years                     | 23 (10)                     |
| Every 3 years                     | 11 (4.8)                    |
| Every 4 years                     | 0                           |
| Every 5 years                     | 1 (0.4)                     |
| > 5 years                         | 0                           |
| **My management of BE with high-grade dysplasia or intramucosal carcinoma is:** |                             |
| Total                             | 244                         |
| Endoscopic treatment              | 188 (77.1)                  |
| Referral to surgery               | 40 (16.4)                   |
| Endoscopic surveillance with eradication treatment in selected cases<sup>a</sup> | 12 (4.9)           |
| Endoscopic surveillance           | 4 (1.6)                     |
| **Which of the following endoscopic techniques do you use to eradicate BE:**    |                             |
| Total                             | 232                         |
| I’m not able to perform any endoscopic eradication treatment                | 186 (37.1)                 |
| I use at least one of the following techniques<sup>b</sup>             | 146 (62.9)                  |
| Endoscopic mucosal resection      | 109 (46.7)                  |
| Radiofrequency ablation           | 69 (29.7)                   |
| Argon plasma coagulation          | 43 (18.5)                   |
| Endoscopic submucosal dissection  | 29 (12.5)                   |
| Multipolar electrocoagulation     | 6 (2.6)                     |

<sup>a</sup> Age < 40 years, BE length > 3 cm, family history for esophageal adenocarcinoma

<sup>b</sup> More than one answer is allowed
The use of incorrect landmark for the GEJ could lead to a misclassification of BE with a negative impact on the early diagnosis of dysplasia and cancer.

No data are available about the use of the “Seattle” biopsy protocol in Europe over the last decade. In our survey, we found that the majority of participants used this standardized biopsy protocol; this data is similar to that reported from surveys in the US [17] and Australia [18].

Current guidelines recommend the use of advanced endoscopic imaging techniques as they increase the likelihood to detect dysplasia and cancer through targeted biopsies [22, 24, 25]. Advanced endoscopy imaging may change BE sampling strategy from the Seattle protocol to targeted biopsies [26]. However, we found that only half of participants used advanced endoscopic techniques routinely, while one third used these techniques only in case of suspected neoplasia. Similar data have been reported by previous surveys in Europe [15] and US [16]. Our findings confirm that there is not yet a widespread use of advanced imaging endoscopy in BE management. Interventions to implement the use of advanced imaging modalities in this setting are certainly warranted.

In our survey, almost all respondents practiced endoscopic surveillance for non-dysplastic BE in accordance with guidelines [19–22, 24, 25]. However, about half of participants performed endoscopic eradication for patients with additional risk factors for esophageal adenocarcinoma, such as age < 40 years, BE length > 3 cm and family history of esophageal cancer [27]. This practice was reported in previous surveys from Europe [15] and US [16, 17], but only by 2% to 12% of participants. Even though the 2012 ASGE guidelines suggested to consider endoscopic ablation for non-dysplastic BE in selected patients with higher risk of cancer [20], current guidelines do not recommend this practice [21, 22, 24, 25] for several reasons including the low incidence of esophageal adenocarcinoma [28], the need of surveillance after ablation for the risk of buried metaplasia [29] and the lack of cost-effectiveness [30]. However, our results may be partially explained by an Italian position paper that suggested ablation therapy for non-dysplastic BE in selected cases [31]. Further research is needed evaluating benefits, risks and costs of this management strategy before it use in clinical practice.

Indeed, according to guidelines patients with non-dysplastic BE should undergo endoscopic surveillance every 3–5 years [20–22, 24, 25]. Recently, in order to reduce unnecessary endoscopy, the timing of surveillance endoscopies has been proposed as a quality indicator in the management of BE [32]. In our survey, one third of participants...
practiced endoscopic surveillance too frequently. Although the adherence to appropriate surveillance intervals has improved substantially over the last years, in US about 40% of patients with non-dysplastic BE still undergo a frequent surveillance (every 1–2 years), resulting in a 40% excess of upper endoscopies over a 10-year surveillance period. Thus, we confirm that there is a overuse of endoscopic surveillance in non-dysplastic BE; unnecessary endoscopies have a negative impact on health-related costs, and may reduce the availability of other appropriate procedures, such as colonoscopies for colorectal cancer screening.

The management of BE with low-grade dysplasia has changed in recent years with endoscopic treatment being preferred to endoscopic surveillance in non-dysplastic BE; unnecessary endoscopies have a negative impact on health-related costs, and may reduce the availability of other appropriate procedures, such as colonoscopies for colorectal cancer screening. As expected, the majority of endoscopists preferred endoscopic therapy to esophagectomy for high-grade dysplasia and early adenocarcinoma, in agreement with international guidelines. Endoscopic mucosal resection and radiofrequency ablation were the most common endoscopic treatments, in line with previous surveys.

We found that endoscopists who attended a training course on BE in the previous 5 years were significantly more likely to use the Prague classification, the top of the gastric folds as landmark for the GEJ and advanced endoscopic imaging techniques. Novel imaging techniques have been introduced only recently in clinical practice and clearly require experience and specific training. Our data would support the need of implementing training courses on the management of BE, mainly focusing on the diagnosis, also by using advanced endoscopy imaging; attending training courses regularly seems to be the best way to keep up with the latest evidence-based strategy for the management of BE.

To our knowledge, this is the largest and more comprehensive survey on practice patterns of endoscopists for the diagnosis and management of BE over the last 10 years in Europe. The ESGE survey, conducted in 2014, included 163 gastroenterologists and only half of them came from European countries. In addition, the ESGE survey did not provide information on several practice patterns, such as the landmark used to identify the GEJ, the use of the “Seattle” biopsy protocol and the frequency of endoscopic surveillance.

This study has several limitations. The main limitation is the low response rate of 31%. However, this response rate is in line with that of previous surveys, ranging from 8% to 45%. Furthermore, a selection bias cannot be excluded, as we do not have information on the characteristics of non-respondents that may differ from those of respondents. For example, our respondents may be more experienced with BE than non-respondents, which may result in an overestimation of the true adherence to guidelines. However, our study sample is similar to the members of SIED in terms of age, gender, area of residence and hospital setting. Furthermore, questionnaire-based surveys have inherent limitations about telling the truth, and responses may be skewed toward adherence to guidelines. Thus, participants may have answered according to what they perceived to be correct rather than according to their practice introducing a response bias. However, given the paucity of data on the practice patterns of endoscopists on the management of BE, our results are valuable.

In conclusion, practice patterns for management of BE among endoscopists are variable. Future efforts should focus on implementing interventions, training courses and educational tools on the management of BE to improve endoscopists’ adherence to guidelines. Particular attention should be given to the diagnosis of BE, including the use of advanced endoscopy imaging, and appropriate surveillance of non-dysplastic BE.

**Acknowledgments** We would like to thank Dr. Italo Stroppa, chair of SIED in 2016, for supporting the study. We acknowledge Dr. Marco Bianchi, Dr. Valentina Boarino and Dr. Elena Cavargini for the contribution in revising the questionnaire. We thank Miss Azzurra Gutling for the technical support provided for the study. Finally, we thank all endoscopists who participated to the survey.

**Funding** Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement. There was no grant support for this study.

**Compliance with Ethical Standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Spechler SJ, Souza RF. Barrett’s esophagus. *N Engl J Med*. 2014;371:836–845.
2. Coleman HG, Bath S, Murray LJ, et al. Increasing Incidence of Barrett’s oesophagus: a population-based study. *Eur J Epidemiol*. 2011;26:739–745.
3. Mascelee GMC, Coloma PM, de Wilde M, et al. The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off. *Aliment Pharmacol Ther*. 2014;39:1321–1330.
4. Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. *Gastroenterol Clin N Am*. 2015;44:203–231.
5. Coleman HG, Xie SH, Lagergren J. The epidemiology of oesophageal adenocarcinoma. *Gastroenterology*. 2018;154:390–405.
6. Sharma P, Dent J, Armostrong D, et al. The development and validation of an endoscopic grading system for Barrett’s oesophagus: the Prague C&M criteria. *Gastroenterology*. 2006;131:1392–1399.
7. Levin DS, Blount PL, Rudolph RE, Reid BJ. Safety of a systematic endoscopic biopsy protocol in patients with Barrett’s oesophagus. *Am J Gastroenterol*. 2000;95:1152–1157.
8. Quemseya BJ, Wang H, Badie N, et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta-analysis and systematic review. *Clin Gastroenterol Hepatol*. 2013;11:1562–1570.
9. Codipilly DC, Chandar AK, Singh S, et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. *Gastroenterology*. 2018;154:2068–2086.
10. Anders M, Bähr C, El-Masry MA, et al. Long-term recurrence of neoplasia and Barrett’s epithelium after complete endoscopic resection. *Gut*. 2014;63:1535–1543.
11. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2013;11:1245–1255.
12. Clermont M, Falk GW. Clinical guidelines update on the diagnosis and management of Barrett’s esophagus. *Dig Dis Sci*. 2018;63:2122–2128. https://doi.org/10.1007/s10602-018-5070-z.
13. Cruz-Correa M, Gross CP, Canto ML, et al. The impact of practice guidelines in the management of Barrett’s esophagus. *Arch Intern Med*. 2001;161:2588–2595.
14. Roumans CAM, van der Boga RD, Steyerberg EW, et al. Adherence to recommendations of Barrett’s esophagus surveillance guidelines: a systematic review and meta-analysis. *Endoscopy*. 2019;52:17–28.
15. Dunn SJ, Neilson LJ, Hassan C, Sharma P, Guy C, Rees CJ. ESGE Survey: worldwide practice patterns amongst gastroenterologists regarding the endoscopic management of Barrett’s esophagus. *Endosc Int Open*. 2016;4:E36–E41.
16. Singh M, Gupta N, Gaddam S, et al. Practice patterns among U.S. gastroenterologists regarding endoscopic management of Barrett’s esophagus. *Gastrointest Endosc*. 2013;78:689–695.
17. Menezes A, Tierney A, Yang Y-X, et al. Adherence to the 2011 American Gastroenterological Association medical position statement for the diagnosis and management of Barrett’s esophagus. *Dis Esophagus*. 2015;28:538–546.
18. Farfus AW, Griffiths EA, Thompson SK, Devitt PG. Current Australian practice in the diagnosis and management of Barrett’s esophagus. *ANZ J Surg*. 2013;83:895–898.
19. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association position statement on the management of Barrett’s esophagus. *Gastroenterology*. 2011;140:1084–1091.
20. Evans JA, Early DS, Fukami N, et al. ASGE Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of esophagus. *Gastrointest Endosc*. 2012;76:1087–1094.
21. Fitzgerald RC, Di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. *GUT*. 2014;63:7–42.
22. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. *Am J Gastroenterol*. 2016;111:30–50.
23. Schölvink DW, Goto O, Seldendijk CA, et al. Detection of pali-sade vessels as a landmark for Barrett’s esophagus in a Western population. *J Gastroenterol*. 2016;51:682–690.
24. Weusten B, Bisschops R, Coren E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. *Endoscopy*. 2017;49:191–198.
25. Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. *Gastrointest Endosc*. 2019;90:335–359.
26. Brown J, Sharma P. From Prague to Seattle: improved endoscopic technique and reporting improves outcomes in patients with Barrett’s esophagus. *Dig Dis Sci*. 2016;61:4–5. https://doi.org/10.1007/s10602-015-3958-4.
27. Krishnamoorthi R, Singh S, Raganathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2018;16:1046–1055.
28. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, et al. An accurate cancer incidence in Barrett’s esophagus: a best estimate using published data and modeling. *Gastroenterology*. 2015;149:577–585.
29. Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic resection for Barrett’s esophagus: a systematic review. *Am J Gastroenterol*. 2011;106:1899–1908.
30. Kroep S, Heberle CR, Curtius K, et al. Radiofrequency ablation of Barrett’s esophagus reduces esophageal adenocarcinoma incidence and mortality in a comparative modeling analysis. *Clin Gastroenterol Hepatol*. 2017;15:1471–1474.
31. Costamagna G, Battaglia G, Repici A, et al. Diagnosis and endoscopic management of Barrett’s esophagus: an Italian expert’s opinion based document. *Dig Liver Dis*. 2017;49:1306–1313.
32. Sharma P, Katzka DA, Gupta N, et al. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. *Gastroenterology*. 2015;149:1599–1606.
33. Wani S, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Over-utilization of repeat upper endoscopy in patients with non-dysplastic Barrett’s esophagus: a quality registry study. *Am J Gastroenterol*. 2019;114:1256–1264.
34. Wani S, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Time trend in adherence to surveillance intervals and biopsy protocol among patients with Barrett’s esophagus. *Gastroenterology*. 2020;158:770–772.

35. Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer ASGE Standard of Practice Committee. *Gastrointest Endosc*. 2018;87:907–931.

36. Sharma P, Shaheen NJ, Katzka D, Bergman JJ. AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and/or early cancer: expert review. *Gastroenterology*. 2020;158:760–769.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.